Advanced Solid Malignancies

Oncology·MeSH: Breast Neoplasms

15 drugs in development·4 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
azd1390	ASTRAZENECA PLC (AZN)
Cetuximab	BRISTOL MYERS SQUIBB CO (BMY)
rosuvastatin	ASTRAZENECA PLC (AZN)

Phase 2(2)

Drug	Company
AZD9574	ASTRAZENECA PLC (AZN)
LEE011	Novartis AG (NVS)

Phase 1(6)

Drug	Company
[11C]AZ1419 3391	PTC THERAPEUTICS, INC. (PTCT)
AZD9574	PTC THERAPEUTICS, INC. (PTCT)
Datopotamab Deruxtecan	PTC THERAPEUTICS, INC. (PTCT)
digoxin	ASTRAZENECA PLC (AZN)
furosemide	ASTRAZENECA PLC (AZN)
rabeprazole	ASTRAZENECA PLC (AZN)

Phase 1/Phase 2(3)

Drug	Company
[11C]AZ1419 3391	ASTRAZENECA PLC (AZN)
lee011	Novartis AG (NVS)
Temozolomide	ASTRAZENECA PLC (AZN)

Phase 4(1)

Drug	Company
BMS-986523	BRISTOL MYERS SQUIBB CO (BMY)

Compare drugs

azd1390 vs Cetuximab azd1390 vs rosuvastatin azd1390 vs AZD9574

Frequently asked questions

How many drugs are in development for Advanced Solid Malignancies?

BioSniper tracks 15 drugs in development for Advanced Solid Malignancies across 4 companies.

How many clinical trials target Advanced Solid Malignancies?

There are 4 clinical trials targeting Advanced Solid Malignancies tracked by BioSniper.

Deep-dive into Advanced Solid Malignancies

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Advanced Solid Malignancies — Drugs in Development & Clinical Trials | BioSniper